Skip to content

Triamcinolone Assisted Anterior Vitrectomy

Triamcinolone Assisted Anterior Vitrectomy in Complicated Cataract Surgery and Anterior Segment Reconstruction

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01051648
Enrollment
10
Registered
2010-01-18
Start date
2007-12-31
Completion date
2008-06-30
Last updated
2010-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract, Vitrectomy

Keywords

Triamcinolone acetenoide, anterior vitrectomy, presence of vitreous in the anterior chamber., effect of triamcinolone injection on IOP,intraocular infection

Brief summary

Injecting Triamcinolone acetenoide for visualizing and removing vitreous from the anterior chamber.

Detailed description

The research followed the tenets of the Declaration of Helsinki, ;informed consent were obtained from patients where all details of the procedure were explained with emphasis on the intended outcome. The research was approved by the institutional review board. Ten eyes of 10 patients were divided into 2 groups. Group A included 6 eyes of 6 patients with accidental rupture of posterior capsule during cataract surgery (5 eyes underwent phacoemulsification technique and one underwent ECCE). Group B included four eyes of 4 patients undergoing anterior segment reconstruction (anterior vitrectomy, secondary IOL Implantation and iris repair by direct approximation using 10/0 prolene sutures). In group A the mean age was 68.1 ± 10.93 years (range 47 to 79 years), 3 were males and 3 were females. In group B the mean age was 14 ± 5.6 years (range 9 to 22 years), 3 were males and one female. Demographic data and pre-operative Information are presented in table 1 and 2. In all patients triamcinolone acetonide was prepared by keeping the bottle vertical to allow sedimentation of crystals thus removing the vehicle. It was then injected into the anterior chamber (2 ml with concentration 20 mg/ml) just prior to anterior vitrectomy. The direction of the tip of the needle was kept away from the corneal endothelium to minimize endothelial toxicity. Triamcinolone was removed as quickly & completely as possible after finishing anterior vitrectomy. Postoperative regimen included topical steroids and antibiotics for about 4-6 weeks. Topical anti-glaucoma drugs were used in cases of high postoperative IOP for few days until stabilization of IOP. Follow up period ranged from 2 months up to 27 months.

Interventions

DRUGIntra ocular injection of triamcinolone acetonide

In all patients triamcinolone acetonide was prepared by keeping the bottle vertical to allow sedimentation of crystals thus removing the vehicle. It was then injected into the anterior chamber (2 ml with concentration 20 mg/ml) just prior to anterior vitrectomy. The direction of the tip of the needle was kept away from the corneal endothelium to minimize endothelial toxicity. Triamcinolone was removed as quickly & completely as possible after finishing anterior vitrectomy

Sponsors

AL-Nour Eye Hospital
CollaboratorOTHER
Kasr El Aini Hospital
CollaboratorOTHER
Cairo University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
47 Years to 79 Years
Healthy volunteers
No

Inclusion criteria

* Patients with vitreous in the anterior chamber whether in * complicated cataract surgery * disorganized anterior segment structures

Exclusion criteria

* Glaucoma patients * Intra ocular infections * Bacterial or fungal

Design outcomes

Primary

MeasureTime frame
Proper visualization of vitreous strands in the anterior chamber of the eyeimmediately

Secondary

MeasureTime frame
intraocular pressure rise2-3 weeks

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026